A nasopharyngeal cancer diagnostic kit, P85-Ab, developed under Xiamen University's leadership, has recently been approved for market release. Using a new serological marker, it raises early detection rates for nasopharyngeal cancer from 70% to 97.4%. Another diagnostic kit, the BNLF2b EB virus antibody test kit (based on magnetic particle chemiluminescence) developed by Xiamen University and Wantai BioPharm, is reportedly the first of its kind worldwide. The test kit operates by collecting blood, separating serum or plasma, and using an automated instrument to complete detection within 30 minutes, with results available in as little as one hour from blood collection.
